-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Immunotherapy of Acquired Hemophilia A

Program: Education Program
Session: Acquired Hemophilia A Diagnosis and Management
Hematology Disease Topics & Pathways:
Bleeding and Clotting, bleeding disorders, hemophilia, Diseases
Saturday, December 9, 2023, 9:30 AM-10:45 AM

Andreas Tiede, MD

Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

Disclosures: Tiede: Bayer: Honoraria, Research Funding; Biomain: Honoraria; Biotest: Honoraria, Research Funding; Chugai/Roche: Honoraria, Research Funding; CSL Behring: Honoraria; Novo Nordisk: Honoraria, Research Funding; Octapharma: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; SOBI: Honoraria, Research Funding; Takeda: Honoraria, Research Funding.

OffLabel Disclosure: Rituximab, mycofenolate mofetil, emicizumab, and cyclophosphamide are off-label medications for acquired hemophilia A.

See more of: Acquired Hemophilia A Diagnosis and Management
See more of: Education Program
<< Previous Presentation | Next Presentation >>